The NPTX2 antibody targets neuronal pentraxin 2 (NPTX2), a secreted protein belonging to the pentraxin family, which plays a role in synaptic plasticity and neural network formation. NPTX2. also known as neuronal activity-regulated pentraxin (Narp), is primarily expressed in excitatory neurons and regulates AMPA receptor clustering at synapses, influencing long-term strengthening of neural connections. Structurally, it contains an N-terminal coiled-coil domain and a C-terminal pentraxin domain, enabling calcium-dependent ligand binding. Dysregulation of NPTX2 has been implicated in neurological disorders, including Alzheimer’s disease, autism spectrum disorders, and schizophrenia, where synaptic dysfunction is a hallmark. The NPTX2 antibody is widely used in neuroscience research to detect protein expression, localization, and interactions in brain tissues or cell models. It aids in studying synaptic remodeling, neurodegeneration, and disease mechanisms. Commercial NPTX2 antibodies are typically developed in rabbit or mouse hosts, validated via Western blot, immunohistochemistry, or immunofluorescence. Recent studies also explore its potential as a biomarker in cerebrospinal fluid for early neurodegenerative disease diagnosis.